糖脂代谢紊乱流行病学及糖脂代谢病分期诊治

Glucolipid Metabolic Disorders: epidemiology,staging and management

糖脂代谢性疾病的危害在于长期糖、脂、血压水平异常对全身脏器的损害进而导致其功能逐渐减退,是造成患者致残、致死的重要原因,已成为严重威胁健康的重大公共卫生问题。基于长期临床实践和研究,本团队率先提出"糖脂代谢病"创新理论,将糖代谢异常、脂代谢异常、高血压及非酒精性脂肪性肝病(NAFLD)等疾病进行整体认识和一体化防控。最新的流行病学研究显示,糖尿病、血脂异常、NAFLD等患病率增长迅速。近10年来,此类疾病合病/并病的危害逐渐引起重视。2008—2009年本团队调查首先发现,高脂血症患者合并糖尿病、高血压的占84.2%。2012年的3B研究显示,2型糖尿病患者合并血脂异常、高血压的占72%。依据共同存在的病理机制、疾病进程,我们将糖脂代谢病分为3期诊治,对指导临床诊疗和提高防控效果意义重大。

Glucolipid metabolism disorder with chronic abnormal levels of glucose,lipid and blood pressure leading to the gradual decline of whole body function,which is a crucial cause of morbidity and mortality and has become a major public health threaten.Based on long-term research and clinical practice,our team for the first time proposed the novel theory of "Glucolipid Metabolic Disorders (GLMD)" and took the lead in the overall understanding,integrated prevention and control of glycolipid metabolism disorders including glucose metabolism disorder,lipid metabolism disorder,hypertension,non-alcoholic fatty liver disease,overweight and so on.The latest epidemiological research shows that the prevalence rate of patients suffering from diabetes mellitus,dyslipidemia,non-alcoholic fatty liver disease and so on,is increasing rapidly.During the past 10 years,the harm of glucolipid metabolism disorder with complications or concomitant diseases has gradually attracted great interests and attention.A survey from our team conducted from 2008 to 2009 reported that 84.2% of patients with hyperlipidemia had diabetes,hypertension and other diseases.Moreover,the "3B" study conducted from 2010 to 2012 found that 72% of T2DM patients were associated with hypertension and/or dyslipidemia.Here we proposed the clinical staging of GLMD with three diagnosis stages and the according treatment strategies,which will provide clinical guidance and significantly contribute to the improvement on the prevention and treatment of GLMD.